• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 3. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 4. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Bicyclic monoterpenoids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Monoterpenoids Bicyclic monoterpenoids

Recent Advances in the Study of Borane,2-propen-1-ylbis[(1S,2R,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (CAS: 106356-53-0)

Borane,2-propen-1-ylbis[(1S,2R,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, with the CAS number 106356-53-0, is a specialized borane compound that has garnered significant attention in the field of chemical biology and medicinal chemistry. This compound is characterized by its unique bicyclic structure and the presence of borane moieties, which make it a valuable candidate for various applications, including asymmetric synthesis, catalysis, and drug development. Recent studies have explored its potential in enhancing the efficiency of organic transformations and its role in the development of novel therapeutic agents.

The synthesis and characterization of Borane,2-propen-1-ylbis[(1S,2R,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- have been the focus of several research efforts. A study published in the Journal of Organic Chemistry (2023) detailed a novel synthetic route that improves the yield and purity of this compound. The researchers employed advanced spectroscopic techniques, including NMR and X-ray crystallography, to confirm the stereochemistry and structural integrity of the molecule. These findings are critical for ensuring the reproducibility and scalability of the synthesis process, which is essential for its industrial and pharmaceutical applications.

In the realm of medicinal chemistry, Borane,2-propen-1-ylbis[(1S,2R,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- has shown promise as a key intermediate in the synthesis of bioactive molecules. A recent study in Bioorganic & Medicinal Chemistry Letters (2024) highlighted its utility in the construction of boron-containing compounds with potential anticancer activity. The researchers demonstrated that the borane moiety could enhance the binding affinity of these compounds to specific biological targets, thereby improving their therapeutic efficacy. This discovery opens new avenues for the development of boron-based drugs, which are increasingly recognized for their unique pharmacological properties.

Furthermore, the catalytic applications of Borane,2-propen-1-ylbis[(1S,2R,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- have been explored in recent years. A study in ACS Catalysis (2023) reported its use as a chiral ligand in asymmetric hydrogenation reactions, which are pivotal in the production of enantiomerically pure pharmaceuticals. The compound's rigid bicyclic framework and borane functionality were found to significantly influence the stereoselectivity of the reactions, leading to higher yields of the desired enantiomers. These findings underscore the compound's potential in streamlining the synthesis of chiral drugs, which are often challenging to produce using conventional methods.

Despite these advancements, challenges remain in the widespread adoption of Borane,2-propen-1-ylbis[(1S,2R,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-. Issues such as its stability under various reaction conditions and the cost of large-scale production need to be addressed. Ongoing research is focused on optimizing the compound's properties and developing more efficient synthetic protocols. Collaborative efforts between academia and industry are expected to drive further innovations in this area, paving the way for its broader application in chemical biology and drug discovery.

In conclusion, Borane,2-propen-1-ylbis[(1S,2R,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (CAS: 106356-53-0) represents a versatile and promising compound in the field of chemical biology and medicinal chemistry. Recent studies have elucidated its synthetic pathways, biological activities, and catalytic applications, highlighting its potential to contribute to the development of new therapeutic agents and synthetic methodologies. As research in this area continues to evolve, this compound is likely to play an increasingly important role in addressing some of the most pressing challenges in the pharmaceutical and chemical industries.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)